US20120053253A1 - Gene signatures for cancer prognosis - Google Patents
Gene signatures for cancer prognosis Download PDFInfo
- Publication number
- US20120053253A1 US20120053253A1 US13/178,380 US201113178380A US2012053253A1 US 20120053253 A1 US20120053253 A1 US 20120053253A1 US 201113178380 A US201113178380 A US 201113178380A US 2012053253 A1 US2012053253 A1 US 2012053253A1
- Authority
- US
- United States
- Prior art keywords
- genes
- cancer
- expression
- test
- ccgs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/178,380 US20120053253A1 (en) | 2010-07-07 | 2011-07-07 | Gene signatures for cancer prognosis |
US14/632,888 US10954568B2 (en) | 2010-07-07 | 2015-02-26 | Gene signatures for cancer prognosis |
US15/060,090 US20160355884A1 (en) | 2010-07-07 | 2016-03-03 | Gene signatures for cancer prognosis |
US15/921,416 US20180334722A1 (en) | 2010-07-07 | 2018-03-14 | Gene signatures for cancer prognosis |
US17/678,357 US20220259675A1 (en) | 2010-07-07 | 2022-02-23 | Gene signatures for cancer prognosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36220910P | 2010-07-07 | 2010-07-07 | |
US13/178,380 US20120053253A1 (en) | 2010-07-07 | 2011-07-07 | Gene signatures for cancer prognosis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/632,888 Continuation US10954568B2 (en) | 2010-07-07 | 2015-02-26 | Gene signatures for cancer prognosis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120053253A1 true US20120053253A1 (en) | 2012-03-01 |
Family
ID=45441805
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/178,380 Abandoned US20120053253A1 (en) | 2010-07-07 | 2011-07-07 | Gene signatures for cancer prognosis |
US14/632,888 Active US10954568B2 (en) | 2010-07-07 | 2015-02-26 | Gene signatures for cancer prognosis |
US15/060,090 Abandoned US20160355884A1 (en) | 2010-07-07 | 2016-03-03 | Gene signatures for cancer prognosis |
US15/921,416 Abandoned US20180334722A1 (en) | 2010-07-07 | 2018-03-14 | Gene signatures for cancer prognosis |
US17/678,357 Pending US20220259675A1 (en) | 2010-07-07 | 2022-02-23 | Gene signatures for cancer prognosis |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/632,888 Active US10954568B2 (en) | 2010-07-07 | 2015-02-26 | Gene signatures for cancer prognosis |
US15/060,090 Abandoned US20160355884A1 (en) | 2010-07-07 | 2016-03-03 | Gene signatures for cancer prognosis |
US15/921,416 Abandoned US20180334722A1 (en) | 2010-07-07 | 2018-03-14 | Gene signatures for cancer prognosis |
US17/678,357 Pending US20220259675A1 (en) | 2010-07-07 | 2022-02-23 | Gene signatures for cancer prognosis |
Country Status (4)
Country | Link |
---|---|
US (5) | US20120053253A1 (fr) |
EP (2) | EP2591126B1 (fr) |
CA (1) | CA2804391A1 (fr) |
WO (1) | WO2012006447A2 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014078700A1 (fr) | 2012-11-16 | 2014-05-22 | Myriad Genetics, Inc. | Signatures génétiques utilisées en vue du pronostic d'un cancer |
WO2015127101A1 (fr) * | 2014-02-19 | 2015-08-27 | The Trustees Of Columbia University In The City Of New York | Procédé et composition pour le diagnostic du cancer agressif de la prostate |
WO2015175692A1 (fr) | 2014-05-13 | 2015-11-19 | Myriad Genetics, Inc. | Signatures génétiques utilisées en vue du pronostic d'un cancer |
WO2017120456A1 (fr) | 2016-01-06 | 2017-07-13 | Myriad Genetics, Inc. | Gènes et signatures génétiques pour le diagnostic et le traitement du mélanome |
US9758829B2 (en) | 2012-06-22 | 2017-09-12 | Htg Molecular Diagnostics, Inc. | Molecular malignancy in melanocytic lesions |
WO2017193062A1 (fr) | 2016-05-06 | 2017-11-09 | Myriad Genetics, Inc. | Signatures génétiques utilisées en vue du pronostic de cancer rénal |
US10196697B2 (en) | 2013-12-12 | 2019-02-05 | Almac Diagnostics Limited | Prostate cancer classification |
WO2019232435A1 (fr) * | 2018-06-01 | 2019-12-05 | Grail, Inc. | Systèmes et méthodes de réseaux neuronaux convolutifs permettant la classification de données |
US11581062B2 (en) | 2018-12-10 | 2023-02-14 | Grail, Llc | Systems and methods for classifying patients with respect to multiple cancer classes |
US11746380B2 (en) | 2016-10-05 | 2023-09-05 | University Of East Anglia | Classification and prognosis of cancer |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
WO2012006447A2 (fr) | 2010-07-07 | 2012-01-12 | Myriad Genetics, Inc. | Signatures génétiques utilisées pour le pronostic du cancer |
US9605319B2 (en) | 2010-08-30 | 2017-03-28 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
WO2012135008A1 (fr) * | 2011-03-26 | 2012-10-04 | Oregon Health And Science University | Prédicteurs d'expression génique pour le pronostic du cancer |
EP2744919A4 (fr) * | 2011-08-19 | 2015-04-08 | Myriad Genetics Inc | Signatures de gène pour pronostic de cancer du poumon et sélection de thérapie |
US9790556B2 (en) | 2012-01-05 | 2017-10-17 | Centre National De La Recherche Scientifique (Cnrs) | Signature for the diagnosis of lung cancer aggressiveness and genetic instability |
GB201200507D0 (en) * | 2012-01-13 | 2012-02-22 | Isis Innovation | Biomarker |
EP4043580A1 (fr) | 2013-03-15 | 2022-08-17 | Myriad myPath, LLC | Gènes et signatures génétiques pour le diagnostic et le traitement du mélanome |
CN105793437B (zh) * | 2013-09-23 | 2020-12-15 | 芝加哥大学 | 关于dna损伤制剂用于癌症治疗的方法和组合物 |
EP3134548A4 (fr) * | 2014-04-23 | 2018-02-28 | Myriad Genetics, Inc. | Signatures de pronostic du cancer |
AU2015284460B2 (en) | 2014-07-02 | 2021-10-07 | Myriad Mypath, Llc | Genes and gene signatures for diagnosis and treatment of melanoma |
WO2020099277A1 (fr) | 2018-11-13 | 2020-05-22 | Bracco Imaging Spa | Signatures génétiques pour le pronostic de récidive de cancer de la prostate |
EP3901288A1 (fr) * | 2020-04-20 | 2021-10-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Dosage d'expression multigénique pour le carcinome de la prostate |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090555A (en) | 1997-12-11 | 2000-07-18 | Affymetrix, Inc. | Scanned image alignment systems and methods |
US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
US5733729A (en) | 1995-09-14 | 1998-03-31 | Affymetrix, Inc. | Computer-aided probability base calling for arrays of nucleic acid probes on chips |
US6586806B1 (en) | 1997-06-20 | 2003-07-01 | Cypress Semiconductor Corporation | Method and structure for a single-sided non-self-aligned transistor |
US6409664B1 (en) | 1997-07-01 | 2002-06-25 | Michael W. Kattan | Nomograms to aid in the treatment of prostatic cancer |
US5993388A (en) | 1997-07-01 | 1999-11-30 | Kattan; Michael W. | Nomograms to aid in the treatment of prostatic cancer |
DE69823206T2 (de) | 1997-07-25 | 2004-08-19 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Verfahren zur herstellung einer bio-informatik-datenbank |
US6420108B2 (en) | 1998-02-09 | 2002-07-16 | Affymetrix, Inc. | Computer-aided display for comparative gene expression |
WO1999009218A1 (fr) | 1997-08-15 | 1999-02-25 | Affymetrix, Inc. | Detection des polymorphismes a l'aide de la theorie des grappes |
JP3565025B2 (ja) | 1998-07-07 | 2004-09-15 | 日産自動車株式会社 | 治具交換装置および治具交換方法 |
US6185561B1 (en) | 1998-09-17 | 2001-02-06 | Affymetrix, Inc. | Method and apparatus for providing and expression data mining database |
CA2359816C (fr) * | 1999-01-06 | 2010-08-03 | Genenews Inc. | Technique de detection de transcrits geniques dans le sang et leur utilisation |
US20030097222A1 (en) | 2000-01-25 | 2003-05-22 | Craford David M. | Method, system, and computer software for providing a genomic web portal |
US20020183936A1 (en) | 2001-01-24 | 2002-12-05 | Affymetrix, Inc. | Method, system, and computer software for providing a genomic web portal |
US20030120432A1 (en) | 2001-01-29 | 2003-06-26 | Affymetrix, Inc. | Method, system and computer software for online ordering of custom probe arrays |
US20030100995A1 (en) | 2001-07-16 | 2003-05-29 | Affymetrix, Inc. | Method, system and computer software for variant information via a web portal |
US6585606B2 (en) | 2001-07-16 | 2003-07-01 | Thomas S. Penrose | Golf club accessory |
EP3115470B1 (fr) | 2002-03-13 | 2018-07-18 | Genomic Health, Inc. | Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie |
US20030235816A1 (en) | 2002-03-14 | 2003-12-25 | Baylor College Of Medicine (By Slawin And Shariat) | Method to determine outcome for patients with prostatic disease |
US20040049354A1 (en) | 2002-04-26 | 2004-03-11 | Affymetrix, Inc. | Method, system and computer software providing a genomic web portal for functional analysis of alternative splice variants |
US6809118B2 (en) | 2002-07-25 | 2004-10-26 | Yih-Lin Chung | Methods for therapy of radiation cutaneous syndrome |
EP1422526A1 (fr) * | 2002-10-28 | 2004-05-26 | MTM Laboratories AG | Procédé ameliorée de diagnostic des dysplasies |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
JP4568716B2 (ja) | 2003-02-20 | 2010-10-27 | ジェノミック ヘルス, インコーポレイテッド | 遺伝子発現を測定するためのイントロンrnaの使用 |
CA2527285A1 (fr) | 2003-05-28 | 2004-12-23 | Genomic Health, Inc. | Marqueurs de l'expression genetique permettant de predire la reponse une chimiotherapie |
EP3470535B1 (fr) | 2003-06-24 | 2020-04-01 | Genomic Health, Inc. | Prédiction de probabilité de récurrence de cancer |
WO2005007830A2 (fr) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Procedes et compositions pour diagnostic, stadage et pronostic du cancer de la prostate |
EP1709152A4 (fr) * | 2003-12-15 | 2007-11-07 | Univ California | Signature moleculaire du suppresseur de tumeur pten |
ES2550614T3 (es) | 2004-04-09 | 2015-11-11 | Genomic Health, Inc. | Marcadores de expresión génica para predecir la respuesta a la quimioterapia |
JP2007532142A (ja) | 2004-04-23 | 2007-11-15 | エグザジェン ダイアグノスティクス インコーポレイテッド | 乳がん遺伝子発現バイオマーカー |
JP4874234B2 (ja) * | 2004-08-10 | 2012-02-15 | オンコセラピー・サイエンス株式会社 | 非小細胞肺癌関連遺伝子ANLN、およびそのRhoAとの相互作用 |
CA3061785A1 (fr) | 2004-11-05 | 2006-05-18 | Genomic Health, Inc. | Prediction de reaction a la chimiotherapie au moyen de marqueurs d'expression genique |
WO2006052731A2 (fr) | 2004-11-05 | 2006-05-18 | Genomic Health, Inc. | Indicateurs moleculaires de pronostic de cancer du sein et prediction de reponse de traitement |
US20070059720A9 (en) | 2004-12-06 | 2007-03-15 | Suzanne Fuqua | RNA expression profile predicting response to tamoxifen in breast cancer patients |
WO2006091776A2 (fr) | 2005-02-25 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Biomarqueurs destines a predire la progression d'un cancer de la prostate |
US20070026424A1 (en) | 2005-04-15 | 2007-02-01 | Powell Charles A | Gene profiles correlating with histology and prognosis |
US20080275652A1 (en) | 2005-05-13 | 2008-11-06 | Universite Libre De Bruxelles | Gene-based algorithmic cancer prognosis |
EP1880335A1 (fr) | 2005-05-13 | 2008-01-23 | Universite Libre De Bruxelles | Pronostic algorithmique du cancer base sur les genes gene-based algorithmic cancer prognosis |
US20070099209A1 (en) | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
KR101446626B1 (ko) | 2005-09-02 | 2014-10-06 | 도레이 카부시키가이샤 | 신장암 진단, 신장암 환자 예후 예측을 위한 조성물 및 방법 |
GB0519405D0 (en) * | 2005-09-23 | 2005-11-02 | Univ Aberdeen | Cancer therapy prognosis and target |
US20070128636A1 (en) | 2005-12-05 | 2007-06-07 | Baker Joffre B | Predictors Of Patient Response To Treatment With EGFR Inhibitors |
WO2007067672A2 (fr) | 2005-12-06 | 2007-06-14 | Baylor College Of Medicine | Procede de prediction de progression systemique chez des patients atteints de cancer de la prostate |
US20090215054A1 (en) | 2005-12-13 | 2009-08-27 | Carter Scott L | Prognosis indicators for solid human tumors |
AU2007204826B2 (en) | 2006-01-11 | 2013-01-10 | Genomic Health, Inc. | Gene expression markers for colorectal cancer prognosis |
US7914988B1 (en) | 2006-03-31 | 2011-03-29 | Illumina, Inc. | Gene expression profiles to predict relapse of prostate cancer |
US8338109B2 (en) | 2006-11-02 | 2012-12-25 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
AT504702A1 (de) | 2006-12-22 | 2008-07-15 | Arc Austrian Res Centers Gmbh | Set von tumormarkern |
EP2754720A1 (fr) | 2007-02-23 | 2014-07-16 | Aviaradx, Inc. | Survie et rechute liées au cancer de la prostate |
WO2008104805A2 (fr) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Protéines |
CA2680591A1 (fr) | 2007-03-15 | 2008-09-25 | Genomic Health, Inc. | Marqueurs d'expression de gene pour la prevision de la reponse d'un patient a une chimiotherapie |
ES2304306B1 (es) * | 2007-03-20 | 2009-07-07 | Indas Biotech, S.L.U. | Metodo de diagnostico y/o pronostico de cancer vesical. |
CA2688477C (fr) | 2007-06-01 | 2020-12-22 | The Regents Of The University Of California | Test pronostique multigenique pour le cancer du poumon |
WO2009032915A2 (fr) | 2007-09-06 | 2009-03-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Réseaux, kits et procédés de caractérisation de cancers |
CA2699385A1 (fr) | 2007-09-14 | 2009-03-19 | Ventana Medical Systems, Inc. | Biomarqueurs du cancer de la prostate |
NZ562237A (en) * | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
US8067178B2 (en) | 2008-03-14 | 2011-11-29 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
EP2641978A1 (fr) | 2008-05-12 | 2013-09-25 | Genomic Health, Inc. | Tests pour prédire une sensibilité de patients atteints de cancer à des options de traitement de chimiothérapie |
US20100184063A1 (en) | 2008-05-14 | 2010-07-22 | Ming-Sound Tsao | Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy |
RU2011101382A (ru) | 2008-06-16 | 2012-07-27 | Сайвидон Дайагностикс Гмбх (De) | Молекулярные маркеры для прогноза развития рака |
EP2304631A1 (fr) | 2008-06-16 | 2011-04-06 | Sividon Diagnostics GmbH | Algorithmes de prediction de resultat pour des patientes atteintes de cancer du sein traite par chimiotherapie avec atteinte ganglionnaire |
KR20110036056A (ko) | 2008-06-26 | 2011-04-06 | 다나-파버 캔서 인스티튜트 인크. | 전이와 관련된 시그너처 및 결정인자 및 이의 사용 방법 |
AU2009299862B2 (en) | 2008-10-01 | 2016-02-04 | Noviogendix Research B.V. | Molecular markers in prostate cancer |
US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
EP3118328A1 (fr) * | 2009-01-07 | 2017-01-18 | Myriad Genetics, Inc. | Biomarqueurs du cancer |
EP3021120A1 (fr) | 2009-02-20 | 2016-05-18 | Michael P. Lisanti | Procédé de diagnostic ou de pronostic d'un néoplasme comprenant la détermination du niveau d'expression d'une protéine dans des cellules stromales adjacentes au néoplasme |
US20120039805A1 (en) | 2009-02-20 | 2012-02-16 | Pangea Biosciences, Inc. | Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample |
EP2241634A1 (fr) | 2009-04-16 | 2010-10-20 | Université Libre de Bruxelles | Procédé de diagnostic et outils pour prédire l'efficacité des agents ciblés contre l'activation de chemin IGF-1 dans le cancer |
WO2010127322A1 (fr) | 2009-05-01 | 2010-11-04 | Genomic Health Inc. | Algorithme de profil d'expression génique et analyse de probabilité de récurrence de cancer colorectal et réponse à la chimiothérapie |
US20110123990A1 (en) | 2009-11-23 | 2011-05-26 | Baker Joffre B | Methods To Predict Clinical Outcome Of Cancer |
US20130058924A1 (en) | 2010-02-05 | 2013-03-07 | Myriad Genetics, Incorporated | Hypoxia-related gene signatures for cancer classification |
WO2012006447A2 (fr) | 2010-07-07 | 2012-01-12 | Myriad Genetics, Inc. | Signatures génétiques utilisées pour le pronostic du cancer |
EP2409989A1 (fr) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Procédé pour améliorer le profile de glycosylation d'un anticorps |
WO2012012225A2 (fr) | 2010-07-22 | 2012-01-26 | Mayo Foundation For Medical Education And Research | Prédiction du pronostic de cancer |
ES2611000T3 (es) | 2010-07-27 | 2017-05-04 | Genomic Health, Inc. | Método para usar la expresión génica para determinar el pronóstico de cáncer de próstata |
US9605319B2 (en) | 2010-08-30 | 2017-03-28 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
WO2012106718A2 (fr) | 2011-02-04 | 2012-08-09 | Bioarray Therapeutics, Inc. | Procédés d'utilisation de signatures d'expression génique pour sélectionner un procédé de traitement, prédire un pronostic, la survie, et/ou prédire une réponse à un traitement |
CA2829776A1 (fr) | 2011-03-14 | 2012-09-20 | National Research Council Of Canada | Jeux de marqueurs de pronostic du cancer de la prostate |
WO2012135008A1 (fr) | 2011-03-26 | 2012-10-04 | Oregon Health And Science University | Prédicteurs d'expression génique pour le pronostic du cancer |
CA2835730C (fr) | 2011-05-12 | 2021-06-01 | Noviogendix Research B.V. | Marqueurs moleculaires du cancer de la prostate |
WO2012152800A1 (fr) | 2011-05-12 | 2012-11-15 | Noviogendix Research B.V. | Marqueurs moléculaires dans le cancer de la prostate |
EP2744919A4 (fr) | 2011-08-19 | 2015-04-08 | Myriad Genetics Inc | Signatures de gène pour pronostic de cancer du poumon et sélection de thérapie |
WO2014078700A1 (fr) | 2012-11-16 | 2014-05-22 | Myriad Genetics, Inc. | Signatures génétiques utilisées en vue du pronostic d'un cancer |
-
2011
- 2011-07-07 WO PCT/US2011/043228 patent/WO2012006447A2/fr active Application Filing
- 2011-07-07 CA CA2804391A patent/CA2804391A1/fr active Pending
- 2011-07-07 US US13/178,380 patent/US20120053253A1/en not_active Abandoned
- 2011-07-07 EP EP11804357.9A patent/EP2591126B1/fr active Active
- 2011-07-07 EP EP20210783.5A patent/EP3812469A1/fr active Pending
-
2015
- 2015-02-26 US US14/632,888 patent/US10954568B2/en active Active
-
2016
- 2016-03-03 US US15/060,090 patent/US20160355884A1/en not_active Abandoned
-
2018
- 2018-03-14 US US15/921,416 patent/US20180334722A1/en not_active Abandoned
-
2022
- 2022-02-23 US US17/678,357 patent/US20220259675A1/en active Pending
Non-Patent Citations (1)
Title |
---|
Wu, C-L. et al., PNAS USA, vol. 110, pp. 6121-6125 + Supplement pp. 1-9 (2013) * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9758829B2 (en) | 2012-06-22 | 2017-09-12 | Htg Molecular Diagnostics, Inc. | Molecular malignancy in melanocytic lesions |
EP4190918A1 (fr) | 2012-11-16 | 2023-06-07 | Myriad Genetics, Inc. | Signatures géniques pour le pronostic du cancer |
WO2014078700A1 (fr) | 2012-11-16 | 2014-05-22 | Myriad Genetics, Inc. | Signatures génétiques utilisées en vue du pronostic d'un cancer |
US10196697B2 (en) | 2013-12-12 | 2019-02-05 | Almac Diagnostics Limited | Prostate cancer classification |
WO2015127101A1 (fr) * | 2014-02-19 | 2015-08-27 | The Trustees Of Columbia University In The City Of New York | Procédé et composition pour le diagnostic du cancer agressif de la prostate |
WO2015175692A1 (fr) | 2014-05-13 | 2015-11-19 | Myriad Genetics, Inc. | Signatures génétiques utilisées en vue du pronostic d'un cancer |
EP3623482A1 (fr) | 2014-05-13 | 2020-03-18 | Myriad Genetics, Inc. | Signatures geniques pour le pronostic du cancer |
WO2017120456A1 (fr) | 2016-01-06 | 2017-07-13 | Myriad Genetics, Inc. | Gènes et signatures génétiques pour le diagnostic et le traitement du mélanome |
WO2017193062A1 (fr) | 2016-05-06 | 2017-11-09 | Myriad Genetics, Inc. | Signatures génétiques utilisées en vue du pronostic de cancer rénal |
US11746380B2 (en) | 2016-10-05 | 2023-09-05 | University Of East Anglia | Classification and prognosis of cancer |
US20200005899A1 (en) * | 2018-06-01 | 2020-01-02 | Grail, Inc. | Convolutional neural network systems and methods for data classification |
US11482303B2 (en) * | 2018-06-01 | 2022-10-25 | Grail, Llc | Convolutional neural network systems and methods for data classification |
US20230045925A1 (en) * | 2018-06-01 | 2023-02-16 | Grail, Llc | Convolutional neural network systems and methods for data classification |
CN112888459B (zh) * | 2018-06-01 | 2023-05-23 | 格里尔公司 | 卷积神经网络系统及数据分类方法 |
CN112888459A (zh) * | 2018-06-01 | 2021-06-01 | 格里尔公司 | 卷积神经网络系统及数据分类方法 |
WO2019232435A1 (fr) * | 2018-06-01 | 2019-12-05 | Grail, Inc. | Systèmes et méthodes de réseaux neuronaux convolutifs permettant la classification de données |
US11783915B2 (en) * | 2018-06-01 | 2023-10-10 | Grail, Llc | Convolutional neural network systems and methods for data classification |
US11581062B2 (en) | 2018-12-10 | 2023-02-14 | Grail, Llc | Systems and methods for classifying patients with respect to multiple cancer classes |
Also Published As
Publication number | Publication date |
---|---|
EP2591126A4 (fr) | 2014-01-01 |
EP3812469A1 (fr) | 2021-04-28 |
US20160355884A1 (en) | 2016-12-08 |
WO2012006447A3 (fr) | 2012-05-18 |
WO2012006447A2 (fr) | 2012-01-12 |
US10954568B2 (en) | 2021-03-23 |
EP2591126B1 (fr) | 2020-12-30 |
US20150167103A1 (en) | 2015-06-18 |
US20180334722A1 (en) | 2018-11-22 |
CA2804391A1 (fr) | 2012-01-12 |
EP2591126A2 (fr) | 2013-05-15 |
US20220259675A1 (en) | 2022-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10519513B2 (en) | Cancer Biomarkers | |
US20220259675A1 (en) | Gene signatures for cancer prognosis | |
EP2382331B1 (fr) | Biomarqueurs de cancer | |
US9605319B2 (en) | Gene signatures for cancer diagnosis and prognosis | |
US20210071269A1 (en) | Gene signatures for cancer prognosis | |
US20220112565A1 (en) | Gene signatures for cancer prognosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MYRIAD GENETICS, INC., UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STONE, STEVEN;GUTIN, ALEXANDER;WAGNER, SUSANNE;AND OTHERS;SIGNING DATES FROM 20110714 TO 20110718;REEL/FRAME:026716/0936 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |